3. Adverse events in SCORE.
| Total number of adverse events inSCORE | Comparison of triamcinolone with observation | ||||
| 1 mg triamcinolone | 4 mg triamcinolone | observation | 1 mg vs observation group (RR, CI) | 4 mg vs observation group (RR, CI) | |
| Elevated IOP: | |||||
| ≥ 10 mm Hg | 15/92 (16.3%) | 24/91 (26.4%) | 2/88 (2.3%) | 7.17 (1.69, 30.47) | 11.60 (2.83, 47.65) |
| ≥ 35 mm Hg | 5/92 (5.4%) | 8/91 (8.8%) | 1/88 (1.1%) | 4.78 (0.57, 40.13) | 7.74 (0.99, 60.59) |
| Ocular hypertension: | NR | NR | NR | ‐ | ‐ |
| Eye pain: | NR | NR | NR | ‐ | ‐ |
| Conjunctiva: | |||||
| Hemmorhage | NR | NR | NR | ‐ | ‐ |
| Hyperemia | NR | NR | NR | ‐ | ‐ |
| Cornea/lens: | |||||
| Infection/endophthalmitis | 0/92 (0%) | 0/91 (0%) | 0/88 (0%) | N/A | N/A |
| Cataract/lens opacity | 20/92 (21.7%) | 25/91 (27.5%) | 12/88 (13.6%) | 1.59 (0.83, 3.06) | 2.01 (1.08, 3.76) |
| Iris neovascularization: | 9/92 (9.8%) | 4/91 (4.4%) | 2/88 (2.3%) | 4.30 (0.96, 19.37) | 1.93 (0.36, 10.29) |
| Vitrious: | |||||
| Hemorrhage | 4/92 (4.3%) | 0/91 (0%) | 4/88 (4.5%) | 4.30 (0.96, 19.37) | 1.93 (0.36, 10.29) |
| Detachment | NR | NR | NR | ‐ | ‐ |
| Retina: | |||||
| Neovascularization | 2/92 (2.2%) | 2/91 (2.2%) | 4/88 (4.5%) | 0.48 (0.09, 2.55) | 0.48 (0.09, 2.57) |
| Detachment | 0/92 (0%) | 0/91 (0%) | 0/88 (0%) | N/A | N/A |
| Hemorrhage | NR | NR | NR | ‐ | ‐ |
| Maculopathy | NR | NR | NR | ‐ | ‐ |
| Required additional therapy: | |||||
| IOP lowering medications | 18/92 (19.6%) | 32/91 (35.2%) | 7/88 (8.0%) | 2.46 (1.08, 5.60) | 4.42 (2.06, 9.49) |
| Cataract surgery | 0/92 (0%) | 4/91 (4.4%) | 0/88 (0%) | N/A | N/A |
| Photocoagulation | 9/92 (9.8%) | 3/91 (3.3%) | 5/88 (5.7%) | 1.72 (0.60, 4.94) | 0.58 (0.14, 2.36) |
| Pars plana vitrectomy | 2/92 (2.2%) | 0/91 (0%) | 1/88 (1.1%) | 1.91 (0.18, 20.72) | N/A |
CI: 95% confidence interval IOP: intraocular pressure mg: milligram mm Hg: millimeter of mercury NR: not reported RR: risk ratio